Diabetes affects over 25.8 million people in the United States and its numbers are continuing to grow. Type 1 diabetes (T1D), or juvenile diabetes, affects 5-10% of the total diabetic population. Type 1 diabetes is a chronic autoimmune disease that causes destruction of pancreatic B cells, which ultimately result in loss of insulin production. Recent clinical trials have found that Mesenchymal Stem Cells (MSCs) may be an alternative to treating T1D. MSCs, (the same type of cells used by Celltex), are adult cells that can be taken from a person’s own fat. MSCs hold homing capacity, which helps guide the cells to injured mesenchymal tissue in one’s body. MSCs characteristics of immunomodulatory and trophic activity make MSCs attractive for treating T1D.
Read the full article here.
The post Mesenchymal Stem Cells May Hold The Answer to Fighting Type 1 Diabetes appeared first on Celltex Therapeutics.